SCHEMBL4568430

SCHEMBL4568430

COC(=O)c1cccc(Cc2c(-c3cc(F)cc(Cl)c3)[nH]c3cc(OC)ccc23)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 3/20 0.42
MAPK12 P53778 3/20 0.42
MAPK11 Q15759 3/20 0.42
MAPK14 Q16539 3/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
CYP19A1 P11511 4/20 0.40
MRGPRX4 Q96LA9 2/20 0.39
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
IDH1 O75874 1/20 0.37
PTGER1 P34995 1/20 0.36
MCL1 Q07820 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568537 0.92 MAPK13 (0.43) MAPK13MAPK12MAPK11MAPK14CYP19A1
SCHEMBL4568186 0.90 MAPK13 (0.51) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568179 0.89 CYP19A1 (0.50) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568187 0.89 CYP19A1 (0.50) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568193 0.89 KDM4E (0.42) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568426 0.89 KDM4E (0.45) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568421 0.88 KDM4E (0.46) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL4568433 0.88 MAPK13 (0.42) MAPK13MAPK12MAPK11MAPK14KDM4E
SCHEMBL3706006 0.86 MTNR1A (0.48) KDM4EALDH1A1HPGDHSD17B10TUBB4A
SCHEMBL4568192 0.86 KDM4E (0.42) MAPK13MAPK12MAPK11MAPK14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPK13 3349/4885MAPK12 3318/4885MAPK11 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.